ANVS
Annovis Bio (ANVS)
$
37About Annovis Bio (ANVS)
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.
Details
Daily high
$4.53
Daily low
$4.31
Price at open
$4.49
52 Week High
$22.49
52 Week Low
$4.30
Market cap
60.3M
Dividend yield
0.00%
Volume
330,156
Avg. volume
331,178
P/E ratio
-1.13
Annovis Bio News
Details
Daily high
$4.53
Daily low
$4.31
Price at open
$4.49
52 Week High
$22.49
52 Week Low
$4.30
Market cap
60.3M
Dividend yield
0.00%
Volume
330,156
Avg. volume
331,178
P/E ratio
-1.13